美女免费一级视频在线观看

Fingerpaint Group has secured yet another acquisition to boost its portfolio, this time expanding its market access capabilities. 

On Wednesday, the MM+M 2024 Agency 100 honoree announced that it is adding BlackPoint Consulting Group, a New York-based specialized advisory firm servicing healthcare and life sciences companies, to its portfolio.

Fingerpaint Group did not share the cost of the acquisition, though Fairmount Partners acted as exclusive financial partners to BlackPoint and McDermott Will & Emery provided legal representation throughout the process. 

According to Brannon Cashion, the chief commercial officer and president of specialized services at Fingerpaint Group, the intention behind this acquisition was simple: to boost Fingerpaint’s market access capabilities and range of services.

The private equity-backed agency has a history of inking high-profile acquisitions, including the additions of PharmaHealthLabs and The Mynd Group back in 2023. 

Fingerpaint Group, who has worked with blue-chip pharma clients like Novo Nordisk, Zoetis and Bayer, works with clients on the all stages of drug discovery. 

Both Cashion and Bill McEllen, the global president at Fingerpaint Group, noted that the firm’s clients were interested in additional services, which led the group to look for opportunities to enhance its market access capabilities. 

“Our clients wanted us to go deeper, they value our collaborative approach,” Cashion said. “So when we think about growing, we want to bring in experienced leaders who have been part of drug launches.” 

Enter John Richardson, principal and co-founder of BlackPoint, who brings more than 15 years of experience working in the life sciences industry to get drugs on the market. 

Richardson said he and the leaders at Fingerpaint Group first toyed with the idea of a merger over dinner and walked away from the meal with hope for a deal. 

“It was a no-brainer,” he said. “Historically, we focus on the tail end of the product life cycle. This merger would give us access to a full complimentary suite of clients and be able to provide them with all the services they need throughout the life cycle.”

Specifically, he noted that BlackPoint prioritizes guiding clients through the complicated drug pricing, regulatory and compliance landscape during product launches. 

He said this insight would be useful for Fingerpaint Group’s clients earlier on in the drug discovery process. 

“We know who the vendors are, we know the customers and the partners — whether it’s the payer groups with the PBMs or it’s on the trade side,” he said. “We’re familiar with the best practices and principles, which is useful for clients to know early on.”

The acquisition will also boost Fingerpaint Group’s Market Access Center of Excellence, which offers end-to-end expertise throughout the product lifecycle. 

Going forward, BlackPoint will leverage its expertise in internal operations and market access to enhance operations, strategy around pricing, contracting, marketing and education to drive engagement. 

As it relates to personnel, McEllen emphasized that the current staff at both agencies will be keeping their roles as the merger comes together. 

Beyond being able to offer clients a full suite of product lifecycle services, McEllen said that he’s most excited about the collaboration between the teams moving forward. 

Both parties are still in early stages of the merger, but are hopeful for what the future will hold. 

“This is a partnership that has made us smile,” said Cashion. “It’s going to infuse nice energy into our group.”